​

Upstream Bio (UPB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

UPB Stock Forecast

Upstream Bio (UPB) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $25.00, with a high of $25.00 and a low of $25.00. This represents a 374.38% increase from the last price of $5.27.

UPB Stock Rating

Upstream Bio stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

UPB Price Target Upside V Benchmarks

TypeNameUpside
StockUpstream Bio374.38%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$25.00$34.50
Last Closing Price$5.27$5.27$5.27
Upside/Downside-374.38%554.65%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26162--9
Aug, 26162--9
Jul, 26162--9
Jun, 26251--8
May, 26251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 11, 2026Truist Financial$25.00$7.09252.61%374.38%
Mar 27, 2026Evercore ISI$15.00$8.6773.01%184.63%
Dec 17, 2025Joseph CatanzaroMizuho Securities$51.00$28.3380.02%867.74%
Oct 14, 2025Truist Financial$47.00$20.08134.06%791.84%
Nov 05, 2024Yasmeen RahimiPiper Sandler$75.00$28.02167.67%1323.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2026H.C. WainwrightBuyinitialise
Nov 05, 2024Cowen & Co.Buyinitialise
Nov 05, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.49$-2.66----
Avg Forecast$-8.03$-2.40$-2.78$-2.49$-2.11$-1.60
High Forecast$-5.04$-2.12$-2.16$-2.25$-2.11$-1.60
Low Forecast$-10.17$-2.71$-3.25$-2.73$-2.11$-1.60
Surprise %-81.44%10.83%----

Revenue Forecast

$0 $3M $6M $9M $12M $15M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$2.37M$2.85M----
Avg Forecast$2.15M$1.50M$1.52M$2.27M$6.94M$12.92M
High Forecast$2.72M$1.50M$1.52M$2.27M$6.94M$12.92M
Low Forecast$1.88M$1.50M$1.52M$2.27M$6.94M$12.92M
Surprise %10.10%90.04%----

Net Income Forecast

$-550M $-450M $-350M $-250M $-150M $-50M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-62.81M$-143.44M----
Avg Forecast$-390.56M$-128.56M$-159.74M$-127.94M$-108.33M$-81.98M
High Forecast$-258.77M$-108.65M$-110.90M$-115.56M$-108.33M$-81.98M
Low Forecast$-522.34M$-139.32M$-166.86M$-140.31M$-108.33M$-81.98M
Surprise %-83.92%11.58%----

UPB Forecast FAQ

Is Upstream Bio stock a buy?

Upstream Bio stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Upstream Bio is a favorable investment for most analysts.

What is Upstream Bio's price target?

Upstream Bio's price target, set by 5 Wall Street analysts, averages $25 over the next 12 months. The price target range spans from $25 at the low end to $25 at the high end, suggesting a potential 374.38% change from the previous closing price of $5.27.

How does Upstream Bio stock forecast compare to its benchmarks?

Upstream Bio's stock forecast shows a 374.38% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Upstream Bio over the past three months?

  • September 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 11.11% Strong Buy, 66.67% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Upstream Bio’s EPS forecast?

Upstream Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.78, marking a 4.51% increase from the reported $-2.66 in 2025. Estimates for the following years are $-2.49 in 2027, $-2.11 in 2028, and $-1.6 in 2029.

What is Upstream Bio’s revenue forecast?

Upstream Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $1.52M, reflecting a -46.83% decrease from the reported $2.85M in 2025. The forecast for 2027 is $2.27M, followed by $6.94M for 2028, and $12.92M for 2029.

What is Upstream Bio’s net income forecast?

Upstream Bio's net income forecast for the fiscal year ending in December 2026 stands at $-160M, representing an 11.36% increase from the reported $-143M in 2025. Projections indicate $-128M in 2027, $-108M in 2028, and $-81.976M in 2029.